Penta is proud to be a partner in the Horizon Europe funded “RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) project. Within the project we will be bringing our paediatric expertise and drive to improve health outcomes for children.
During the project’s 2.5-year duration, RBDCOV will test the efficacy, tolerability, and safety of the Covid-19 vaccine in children, adolescents and immunocompromised people.
Read the RBDCOV press release for more on the project.